PACAB-002
Peritoneal micrometastases in High-Grade Serous Ovarian Cancer
Pre-clinicalActive
Key Facts
Indication
Peritoneal micrometastases in High-Grade Serous Ovarian Cancer
Phase
Pre-clinical
Status
Active
Company
About NaDeNo
NaDeNo is a private, preclinical-stage biotech leveraging a proprietary nanotechnology platform to overcome drug delivery hurdles for hydrophobic small molecules. Its core innovation involves locally administered, tissue-adhesive nanoparticles that anchor to target tissues, providing sustained local drug release and bypassing biological barriers. The company is advancing its lead asset, PACAB-002, for ovarian cancer and offers its platform for partnerships, recently securing an EIC Accelerator grant of up to €10 million to fund clinical development.
View full company profile